| Calliditas Therapeutics–Optimum Strategic Communications: public relations, 201711 service existent by Optimum |
2017-11-15 |
| Calliditas Therapeutics–SEVERAL: investment, 202005–202006 private placement SEK82.9m with 924k common shares at SEK89.7/share outside US |
2020-05-14 |
| Calliditas Therapeutics–SEVERAL: investment, 202005–202007 US IPO $81m+$6.9m with w 8.3m+707k common shares as ADSs at Nasdaq Global Market |
2020-05-14 |
| Cardior Pharmaceuticals–Hadean Ventures: investment, 202108 financing round Series B totalling €64m incl new + co-investor Hadean Ventures |
2021-08-25 |
| Cardior Pharmaceuticals–Novo Group: investment, 202403– acquisition for up to €1.025b incl upfront payment + milestones ANNOUNCED |
2024-03-25 |
| Cardior Pharmaceuticals–SEVERAL: investment, 202108 financing round Series B €64m led by new investor Inkef Capital |
2021-08-25 |
| Cardior Pharmaceuticals–Sunstone Life Science: investment, 202108 financing round Series B totalling €64m incl new + co-investor Sunstone |
2021-08-25 |
| Cartana–10x Genomics: investment, 202008 acquisition of Cartana AB by 10x Genomics Inc |
2020-08-31 |
| Cellectricon–Censo Biotechnologies: drug discovery services, 201701– collab offer joint tech access program for human iPSC-based discovery services |
2017-01-26 |
| Cellink–Prellis Biologics: bioprinting technology, 201812– collab commercialisation of holographic bioprinting technology |
2018-12-05 |
| Cellink–SEVERAL: credit, 202103–202603 convertible bonds SEK1.5b at 2.875%pa convertible into B Class shares at SEK598.5/share |
2021-03-12 |
| Cellink–SEVERAL: investment, 201906 capital raising SEK148.5m with institutional investors |
2019-06-18 |
| Cellink–SEVERAL: investment, 202103 capital increase SEK1.5b directed issue of new Class B Shares at SEK420/share |
2021-03-12 |
| Centauri Therapeutics–SEVERAL: investment, 202202 financing round Series A £24m with BIVF + Evotec + Novo REPAIR Impact Fund et al |
2022-02-16 |
| CEPI–CureVac: mRNA vaccine production technology, 201903–202202 collab up to $34m developm of mobile mRNA printing facility |
2019-03-01 |
| Cevec–Danaher: investment, 202210 acquisition of Cevec by Cytiva |
2022-10-06 |
| CH-Bioforce–EU (govt): grant, 202206– EIC Accelerator programme grant up to €15m to advance biomass processing plant |
2022-06-21 |
| Chr. Hansen–Lonza: microbiomic treatment, 201904– collab establishment 50/50 joint venture for developing + manufacturing microbiome treatments |
2019-04-02 |
| Chr. Hansen–Novozymes: investment, 202212– merger acquisition valuing Chr Hansen at DKK660.55/share ANNOUNCED |
2022-12-12 |
| Cinclus Pharma–SEVERAL: investment, 2020 capital increase SEK250m with Fourth AP Fund + Bengt Julander + Jonas Sjögren + Recipharm Venture Fund |
2020-01-01 |
| Cinclus Pharma–SEVERAL: investment, 202204–202205 private placement SEK250m with Trill Impact + Eir Ventures I + Irrus Investments + AP4 + Linc |
2022-04-19 |
| CinCor Pharma–AstraZeneca: investment, 202301–202302 acquisition cash tender offer upfront $1.3b ($26/share) + up to $500m CVR at $10/share |
2023-01-09 |
| Clinical Innovations–EQT: investment, 201710 acquisition by EQT Mid Market US Fund |
2017-10-18 |
| Clinical Microbiomics–BPCE: investment, 202210 investment €10m from Health for Life Capital II fund managed by Seventure Partners |
2022-10-11 |
| CMC Biologics–Asahi Glass: investment, 201612– acquisition JPY60b of 100% of CMC Biologics by Asahi Glass |
2016-12-19 |
| Cobra Biologics–Cognate BioServices: investment, 201911–202001 acquisition of Cobra by Cognate BioServices |
2019-11-04 |
| Cobra Biologics–Zyme Communications: public relations, 201704 service existent by Zyme |
2017-04-18 |
| Cognate BioServices–Charles River: investment, 202102–202103 acquisition $875m in cash by Charles River |
2021-02-17 |
| Cognate BioServices–Essex Woodlands: investment, 202001 financing round Series B incl existing + lead investor EW Healthcare Partners |
2020-01-21 |
| Cognate BioServices–Medivate Partners: investment, 202001 financing round Series B incl co-investor Medivate Partners |
2020-01-21 |
| Cognate BioServices–SEVERAL: investment, 202001 financing round Series B led by EW Healthcare Partners + incl Medivate Partners |
2020-01-21 |
| Colorifix–SEVERAL: investment, 202205 financing round Series B £18m led by H&M CO:LAB |
2022-05-27 |
| CombiGene–United Kingdom (govt): gene therapy manufacturing, 201801– collab developm manufacturing processes for CG01 with CGT Catapult |
2018-01-12 |
| Complement Therapeutics–Hadean Ventures: investment, 202304 financing round Series A totalling €72m incl new + co-investor Hadean Ventures |
2023-04-17 |
| Complement Therapeutics–SEVERAL: investment, 202304 financing round Series A €72m led by new investor Gimv |
2023-04-17 |
| Corvidia Therapeutics–Goodwin Procter: legal services, 202006 supply service legal advisor to Cordivia for acquisition by Novo Nordisk |
2020-06-11 |
| Corvidia Therapeutics–JPMorgan Chase: financial services, 202006 supply service advisor to Cordivia for acquisition by Novo Nordisk |
2020-06-11 |
| Corvidia Therapeutics–Novo Group: investment, 202006 acquisition $725m upfront cash + $1.375b milestones cash by Novo Nordisk ANNOUNCED |
2020-06-11 |
| Corvidia Therapeutics–SEVERAL: investment, 201804 financing round Series B $60m led by Venrock |
2018-04-25 |
| Corvidia Therapeutics–Sofinnova: investment, 2015 seed financing from Sofinnova Partners |
2015-01-01 |
| CorWave–Novo Group: investment, 201611 financing round Series B totalling €15.5m incl new + lead investor Novo Seeds |
2016-11-04 |
| CorWave–Novo Group: investment, 202101 financing round Series C totalling €35m incl existing + co-investor Novo Holdings |
2021-01-06 |
| CorWave–SEVERAL: investment, 202101 financing round Series C €35m led by new investor EIC Fund |
2021-01-06 |
| Curetis–OpGen: investment, 201909– reverse merger with Curetis shareholders holding 72.5% of combined entity |
2019-09-04 |
| CureVac–Genmab: investment, 201912 equity investment €20m by Genmab as part of strategic alliance |
2019-12-19 |
| Cytena–Cellink: investment, 201908 acquisition €30.25m of Cytena GmbH by Cellink AB |
2019-08-05 |
| Cytena–High-Tech Gründerfonds: investment, 201903 financing round Series A totalling €3.m incl HTGF + two private investors |
2019-03-26 |
| Cytena–SEVERAL: investment, 201903 financing round Series A €3m from HTGF + two private investors |
2019-03-26 |
| Cytoki Pharma–+ND Capital: investment, 202105 financing round Series A totalling $45m incl co-investor +ND Captial |
2021-05-05 |
| Cytoki Pharma–BPCE: investment, 202105 financing round Series A totalling $45m incl co-investor Seventure Partners |
2021-05-05 |
| Cytoki Pharma–Lundbeck: investment, 202105 financing round Series A totalling $45m incl existing + lead investor Lundbeckfonden Emerge |
2021-05-05 |
| Cytoki Pharma–SEVERAL: investment, 202105 financing round Series A $45m led by existing investor Lundbeckfonden Emerge |
2021-05-05 |
| Cytoki Pharma–Ysios Capital: investment, 202105 financing round Series A totalling $45m incl co-investor Ysios Capital |
2021-05-05 |
| Cytovation–SEVERAL: investment, 202201 financing round Series A NOK180m (€20m) led by Sandwater + Canica |
2022-01-25 |
| Danaher–Cobo Technologies: protein expression analysis, 201907– collab co-marketing PIPPR platform with SWATH Acquisition + Sciex TripleTOF 6600 |
2019-07-05 |
| Danaher–Evosep: MS-based proteomics, 202111– collab developm proteomics workflows w joint customers using Evosep One + Sciex ZenoTOF 7600 system |
2021-11-01 |
| Dania Therapeutics–Denmark (govt): investment, 202310 financing round totalling DKK15m incl investor EIFO |
2023-10-16 |
| Dania Therapeutics–Eir Ventures: investment, 202310 financing round totalling DKK15m incl investor Eir Ventures |
2023-10-16 |
| Dania Therapeutics–Lundbeck: investment, 202310 financing round totalling DKK15m incl investor Lundbeckfonden BioCapital |
2023-10-16 |
| Dania Therapeutics–SEVERAL: investment, 202310 financing round DKK15m from Lundbeckfonden + EIR Ventures + EIFO + UCPH Ventures |
2023-10-16 |
| Dania Therapeutics–Univ Copenhagen: investment, 202310 financing round totalling DKK15m incl investor UCPH Ventures |
2023-10-16 |
| Danish National Genome Center–Qiagen: genomic software tools, 202306– supply QCI Interpret software for oncology genome sequencing by Qiagen |
2023-06-13 |
| DCprime–Immunicum: investment, 202011– merger with former Immunicum shareholders holding 56% + Van Herk holding 43% of combined company ANNOUNCED |
2020-11-18 |
| Dicerna Pharmaceuticals–Novo Group: investment, 201911 investment $50m by Novo in connection with RnD collab |
2019-11-18 |
| Dicerna Pharmaceuticals–Novo Group: investment, 202111– cash tender offer $38.25/share representing total equity value of $3.3b ANNOUNCED |
2021-11-18 |
| Disc Medicine–AbbVie: therapeutics antibodies, 201910– license €na ww excl to series of hemojuvelin antagonist MAbs from AbbVie |
2019-10-29 |
| Disc Medicine–Novo Group: investment, 201910 financing round Series A totalling $50m incl new + lead investor Novo Holdings A/S |
2019-10-29 |
| Disc Medicine–SEVERAL: investment, 201910 financing round Series A $50m led by Novo Holdings A/S |
2019-10-29 |
| Discover Echo–Cellink: investment, 202106– acquisition $110m with $98m in cash + $12m in new Series B shares ANNOUNCED |
2021-06-26 |
| Dispendix–Cellink: investment, 201812 acquisition €5m of Dispendix GmbH by Cellink AB |
2018-12-01 |
| DiuVita Diagnostics–Dutscher: investment, 202208 acquisition of DiuVita Diagnostics AS by AH Diagnostics AS |
2022-08-31 |
| Dong-A ST–Beactica: cancer drugs, 201610– collab + license agreem multi-year drug development |
2016-10-01 |
| Draupnir Bio–Consilium: public relations, 202109 service existent by Consilium Strategic Communications |
2021-09-23 |
| Draupnir Bio–Novo Group: grant, 201704 grant DKK2.5m (€336k) from Novo Nordisk Foundation at founding |
2017-04-01 |
| ECBF–EU (govt): investment, 201911–202010 first closing totalling €82m incl cornerstone investor EIB that has committed up to €100m |
2019-11-29 |
| ECBF–SEVERAL: investment, 201911–202010 first closing €82m from cornerstone investor EIB + 3 private investors + target size of €250m |
2019-11-29 |
| ECBF–SEVERAL: investment, 202012 2nd closing with additional €93m from new investors bringing total to €175m |
2020-12-15 |
| ECBF–SEVERAL: investment, 202012–202202 raising of additional €125m + final closing of fund at €300m |
2020-12-16 |
| Egle Therapeutics–Life Sciences Partners: investment, 202110 financing round Series A totalling €40m incl co-lead investor LSP Fund 7 |
2021-10-22 |
| Eir Ventures–Denmark (govt): investment, 202007 first closing totalling €76m incl investor Vaekstfonden |
2020-07-10 |
| Eir Ventures–EU (govt): investment, 202007 first closing totalling €76m incl investor EIF |
2020-07-10 |
| Eir Ventures–Novo Group: investment, 202007 first closing totalling €76m incl investor Novo Holdings |
2020-07-10 |
| Eir Ventures–Optimum Strategic Communications: public relations, 202007 service existent by Optimum |
2020-07-10 |
| Eir Ventures–SEVERAL: investment, 202007 first closing €76m from Saminvest + EIF + Vaekstfonden + Novo Holdings + private investors |
2020-07-10 |
| Eir Ventures–SEVERAL: investment, 202112 final closing with additional €46.3m of Eir Ventures I AB fund bringing total to €122.3m |
2020-07-10 |
| Eir Ventures–Sustainable Development Umbrella Fund: investment, 202112 final closing with additional €46.3m of Eir Ventures I AB incl investor SDUF |
2020-07-10 |
| Eir Ventures–Sweden (govt): investment, 202007 first closing totalling €76m incl investor Saminvest |
2020-07-10 |
| Electrochaea–Baker Hughes: investment, 202106–202201 financing round Series D totalling €36m incl lead investor Baker Hughes |
2021-06-28 |
| Electrochaea–EU (govt): grant, 202008 Horizon 2020 EIC Accelerator grant €2.5m |
2020-08-01 |
| Electrochaea–EU (govt): investment, 202106–202201 financing round Series D totalling €36m incl €14.9m from co-lead investor EIC Fund |
2021-06-28 |
| Electrochaea–SEVERAL: investment, 2014 financing round Series A |
2014-01-01 |
| Electrochaea–SEVERAL: investment, 202106–202201 financing round Series D €36m led by Baker Hughes + co-led by EIC Fund |
2021-06-28 |
| Ellab–EQT: investment, 201908–201909 acquisition €na majority share by EQT Mid Market Europe Fund from IK VIII Fund |
2019-08-07 |
| Ellab–Novo Group: investment, 202306– acquisition of Ellab by Novo Holdings from EQT Private Equity + co-shareholders |
2023-06-21 |
| Elypta–Bonnier: investment, 202206 financing round Series A totalling $21m incl lead investor Bonnier Ventures |
2022-06-20 |
| Elypta–Chalmers Univ: investment, 201912 late seed financing round totalling €6.1m incl existing + co-investor Chalmers Ventures |
2019-12-01 |
| Elypta–Chalmers Univ: investment, 202206 financing round Series A totalling $21m incl existing + co-investor Chalmers Ventures |
2022-06-20 |
| Elypta–Hillclimber: investment, 202206 financing round Series A totalling $21m incl existing + co-investor Hillclimber |
2022-06-20 |
| Elypta–Nina Capital: investment, 201912 late seed financing round totalling €6.1m incl co-investor Nina Capital |
2019-12-01 |
| Elypta–Nina Capital: investment, 202206 financing round Series A totalling $21m incl existing + co-investor Nina Capital |
2022-06-20 |
![[LSS] Life-Sciences-Scandinavia.com - The Scandinavian Life Sciences Web Portal](/images/basics/lss-life-sciences-scandinavia-portal-logo.svg){kind=logo}
1 2 3 4 5 6 7 8 9 10 11 
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
